top of page

GLP-1 and the Microbiome: Why Weight-Loss Drugs Work Through Bacteria

4 days ago
8 min read
GLP-1 and the microbiome: why weight-loss drugs work through bacteria — Ediens

GLP-1 drugs — semaglutide, liraglutide, tirzepatide — have become one of the most discussed topics in modern medicine within just a few years. Millions of people worldwide use them to manage weight and blood sugar, and doctors speak of a new era in obesity treatment.

The usual explanation of the mechanism is simple: the drug mimics a satiety hormone, so a person eats less. But that is only part of the picture. The GLP-1 hormone itself is born in the gut, and the gut microbiome — the trillions of bacteria living there — directly influences how much of it the body produces, how quickly it is broken down and how the body responds to therapy.

This does not mean the drugs “work only through bacteria.” The main effect of GLP-1 agonists is delivered through receptors in the brain, pancreas and digestive tract. However, a growing body of research suggests the microbiome is an important co-player: it may strengthen or weaken the response to treatment, influence side effects, and itself change under the influence of the drugs.

In this article we explain what GLP-1 is, how gut bacteria are linked to its production, what research already shows and what remains a hypothesis — and how to support your microbiome in practice if you use or are considering GLP-1 therapy.

1. What GLP-1 is and how weight-loss drugs work

GLP-1 (glucagon-like peptide-1) is an incretin, a hormone that intestinal cells release in response to food. Its natural role is to tell the body that food has arrived and to prepare it for digestion. Native GLP-1 lives in the blood for only minutes, because the enzyme DPP-4 quickly breaks it down.

GLP-1 receptor agonists are degradation-resistant analogues of the hormone. Tirzepatide additionally activates the receptor of another incretin, GIP. Thanks to their long action they create a steady satiety signal that the natural hormone cannot provide.

Main effects of GLP-1 agonists:

  • Satiety centres in the brain: the drug acts on the hypothalamus and brainstem, lowering appetite and “food noise” — intrusive thoughts about eating.

  • Slower gastric emptying: food stays in the stomach longer, so fullness arrives earlier and lasts longer.

  • Glucose-dependent insulin secretion: the pancreas releases insulin when blood sugar is high, which reduces the risk of hypoglycemia.

  • Lower glucagon: the liver releases less glucose between meals.

All these effects concern the hormone and its receptors. But where does endogenous GLP-1 come from, and what determines how much your own body produces? This is where the gut microbiome enters the stage.

2. The gut is a natural GLP-1 factory, and bacteria are its staff

GLP-1 is produced by specialised enteroendocrine L-cells, located mainly in the distal small intestine and the colon — exactly where the largest number of bacteria live. This is no coincidence: L-cells constantly “listen” to what happens in the gut lumen, and microorganisms provide a significant share of the signals they receive.

How bacteria stimulate the body’s own GLP-1:

  • Short-chain fatty acids (SCFAs): bacteria ferment dietary fibre into butyrate, propionate and acetate. These molecules bind to FFAR2 and FFAR3 receptors on L-cells and enhance secretion of GLP-1 and the related peptide YY.

  • Secondary bile acids: the microbiota converts primary bile acids into secondary ones, which activate the TGR5 receptor on L-cells — another route of GLP-1 stimulation.

  • Akkermansia muciniphila: in a mouse study, the P9 protein of this bacterium stimulated GLP-1 secretion and improved glucose metabolism. In a small clinical trial, pasteurised Akkermansia improved insulin sensitivity in people with overweight.

  • Microbial fermentation and the barrier: a healthy microbiome supports gut barrier integrity and reduces low-grade inflammation, which is linked to insulin resistance and obesity.

Why this matters for someone taking the drug:

If the microbiome is depleted and the diet is low in fibre, SCFA production drops. That means less natural stimulation of L-cells and probably a weaker intrinsic satiety “background.” The drug compensates for this deficit from outside but does not remove its cause. This is why combining pharmacotherapy with work on the microbiome is increasingly discussed.

3. What research shows: drugs and bacteria influence each other

The link between GLP-1 agonists and the microbiome runs both ways. On one hand, the composition of the microbiota may influence the response to treatment. On the other, the drugs themselves seem to change the gut ecosystem, although the nature of the changes depends on the study, the drug and the participants.

What is already known:

  • Animal models: in obese mice, semaglutide and liraglutide changed the composition of the microbiota, including the balance between major bacterial groups, and were accompanied by a rise in beneficial SCFA producers.

  • Human data: small studies record shifts in the microbiome during therapy, but results are inconsistent and sample sizes are limited.

  • Variability of response: some patients lose weight much faster than others on the same dose. The microbiome is considered one possible factor behind this difference, alongside genetics, diet and activity level.

  • Co-medications: for metformin it has already been shown that part of its effect is mediated by changes in the microbiota. Researchers are testing similar logic for incretin drugs.

Limitations to keep in mind:

Most mechanistic data come from animals or small groups. It is hard to separate a direct effect of the drug on bacteria from a secondary one: a person loses weight, changes diet, eats less — and the microbiome changes for that reason alone. So the conclusion “the drug changes the microbiome exactly this way” cannot yet be considered final.

Key microbial players in the GLP-1 link

Microbial link

What it does

Connection to GLP-1 and weight

Butyrate producers (Faecalibacterium, Roseburia)

Ferment fibre and produce butyrate

Feed colon cells, support the barrier, stimulate L-cells

Akkermansia muciniphila

Lives in the mucus layer and supports its thickness

P9 protein stimulates GLP-1 secretion (model data), linked to metabolic health

Bifidobacteria and lactobacilli

Ferment oligosaccharides, produce acetate and lactate

Keep the community balanced and feed butyrate producers through cross-feeding

Bile-acid-transforming bacteria

Convert primary bile acids into secondary ones

Activate TGR5 on L-cells and shape the incretin response

Opportunistic groups

Produce LPS and inflammatory metabolites

Sustain low-grade inflammation and insulin resistance

4. Why the response to the drug varies so much and what the gut has to do with it

Clinicians know it well: two people with the same BMI on the same dose can have completely different results and completely different well-being. The microbiome is one reason why the “average” response from clinical trials does not guarantee your personal one.

Typical complaints during therapy and the role of the gut:

  • Nausea and fullness: partly linked to slower gastric emptying. Smaller portions, less fat and slower eating usually help.

  • Constipation: less food means less fibre and less substrate for bacteria. Without enough fibre and water, motility slows even more.

  • Bloating and diarrhea: can appear when changes in diet and digestion speed disturb the balance of fermentation in the colon.

  • Loss of muscle mass: rapid weight loss without enough protein and exercise removes more than fat. And the microbiome takes part in amino acid absorption and metabolism.

All this is a good reason to view GLP-1 therapy not in isolation but as part of a whole: a nutrition strategy, physical activity and the state of the gut ecosystem.

5. Practical steps: how to support the microbiome during GLP-1 therapy

Below are general principles consistent with the available data. They do not replace the advice of the doctor who prescribed the drug and are not a treatment plan.

  • Fibre, daily and gradually: vegetables, legumes, whole grains, berries, flax and chia seeds. Increase the amount slowly so the gut can adapt, and drink enough water.

  • Diversity of plant foods: the wider the range of plants, the wider the range of bacteria that get “fuel.” A common target is 20–30 different plant foods a week.

  • Fermented foods: kefir, plain yogurt, sauerkraut, kimchi, miso without excess salt or sugar — a natural source of live microorganisms.

  • Protein and strength training: to preserve muscle mass during weight loss.

  • Caution with “universal” probiotics: effects are strain-specific. A random set of bacteria in low doses is unlikely to solve a specific problem.

  • Do not replace the drug with supplements or change the dose yourself: any change in therapy is made only with your doctor.

6. The Ediens personal approach: from microbiome analysis to an action plan

General tips work a little for everyone and precisely for no one. Every person’s microbiome is unique, so the support strategy must be individual too. The Ukrainian biotechnology company Ediens, founded under the leadership of Dr. Nadiya Boyko, Doctor of Biological Sciences and professor, builds its system on exactly this principle: measure first, then select.

A. Molecular genetic microbiome analysis (NGS)

16S rRNA sequencing shows the full picture: diversity, the share of Akkermansia and butyrate producers, the ratio of major bacterial groups, the profile of opportunistic microorganisms and metabolic potential. These are the parameters linked to how the gut–metabolism–appetite axis works.

B. Personal nutrition plan Biocode4U

Results are uploaded to the EdiensUniCode (BioQuantum) platform, which matches individual bacterial deficits and excesses with data on how plant components interact with the microbiota. The output is a Microbiome Nutrition Plan: a menu built from available foods that feeds precisely the bacteria you need.

  • Fibre and prebiotics tailored to your profile: not “more vegetables in general,” but those that support your own SCFA producers.

  • Eating behaviour during therapy: a diet that takes reduced appetite and the need for protein and fibre into account.

Biocode4U: Microbiome Nutrition Plan
Buy Now

C. Targeted BioMeCombi pharmabiotics

Ediens pharmabiotics are bio-preparations based on live, genetically passported microorganisms at high concentration, complemented by plant prebiotics. They are not obesity medications and do not replace GLP-1 therapy; they support the gut ecosystem.

  • “Metabolic Antistress”: a psychobiotic based on the author’s strain Lactobacillus plantarum IMB B-7414, considered as support for metabolic balance and stress resilience — which matters, because chronic stress affects both appetite and the microbiome.

  • “My Second Brain. Gut Microbiome”: a complex of live lactobacilli in portioned sachets to support the balance of the gut microbiota.

Pharmabiotic 'Metabolic Antistress'
Buy Now
Pharmabiotic 'My Second Brain. Gut Microbiome'
Buy Now

Conclusions: what to remember

  • GLP-1 is born in the gut. The L-cells that produce it constantly receive signals from bacteria, including via SCFAs, bile acids and individual species such as Akkermansia.

  • Drugs act mainly through receptors, but the microbiome is an important co-player: it may influence response, tolerability and metabolic outcomes.

  • The data are still limited. Many conclusions come from models or small samples, so caution and an evidence-based approach matter more than bold claims.

  • Supporting the microbiome is a sensible addition, not a replacement for therapy. Fibre, a varied diet, protein and exercise work both for those who take the drugs and for those who do not.

This material is for information only and is not medical advice. Decisions about prescribing, dosing or stopping GLP-1 drugs should be made with your doctor. Ediens pharmabiotics are not medicinal products.

Short questions and answers (Q&A)

1. Do GLP-1 drugs really work “through bacteria”?

Not only. The main mechanism is activation of GLP-1 receptors in the brain, pancreas and gastrointestinal tract. However, the hormone itself is produced in the gut, and bacteria influence its secretion through SCFAs, bile acids and other signals. So the microbiome is seen as an important co-player, not the sole mechanism.

No. Probiotics have no proven effect comparable to GLP-1 agonists, and the effect of different strains varies widely. They may be considered as support for the gut ecosystem, but not as a replacement for treatment prescribed by a doctor.

Butyrate producers (Faecalibacterium, Roseburia), Akkermansia muciniphila, as well as bifidobacteria and lactobacilli that form the “food chain” for SCFA producers. Most data on the direct effect of individual species come from models.

Gradually increase fibre, drink enough water, eat a varied plant-based diet and fermented foods, and take care of protein and strength training. Agree any change of dose or regimen with your doctor.

It can be useful to see exactly what your microbiota lacks and to select personal nutrition. NGS gives the full picture: diversity, the share of key bacteria and metabolic potential, on the basis of which an individual plan is built.

💡 Want to support your microbiome during GLP-1 therapy or learn your personal profile? Contact Ediens specialists for an individual consultation!

Ediens website
Facebook
LinkedIn
Instagram
TikTok

Comments

Rated 0 out of 5 stars.
No ratings yet

Add a rating
bottom of page